Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole
2. Cs 706
3. Cs-706
4. Cs706 Cpd
1. 197904-84-0
2. Tg01
3. Cs-706
4. Tg-01
5. R-109339
6. 5x5hb3vz3z
7. 4-[2-(4-ethoxyphenyl)-4-methylpyrrol-1-yl]benzenesulfonamide
8. 4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)benzenesulfonamide
9. Cs 706; R 109339; Tg 01
10. Benzenesulfonamide, 4-(2-(4-ethoxyphenyl)-4-methyl-1h-pyrrol-1-yl)-
11. Apricoxib [usan]
12. Apricoxib [usan:inn]
13. Unii-5x5hb3vz3z
14. Capoxigem
15. Kymena
16. Tg 01
17. Cs 706
18. Apricoxib [inn]
19. Apricoxib (usan/inn)
20. Cs706 Cpd
21. Apricoxib [who-dd]
22. Schembl346028
23. R 109339
24. Chembl1835207
25. Dtxsid60173502
26. Cs701
27. Db12378
28. Tp-1001
29. Tp-2001
30. D08657
31. Q18209480
32. 2-(4-ethoxyphenyl)-4-methyl-1-(4-sulfamoylphenyl)pyrrole
33. 4-methyl-2-(4-ethoxyphenyl)-1-(4-sulfamoylphenyl)pyrrole
34. 2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1h-pyrrole
| Molecular Weight | 356.4 g/mol |
|---|---|
| Molecular Formula | C19H20N2O3S |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 356.11946368 g/mol |
| Monoisotopic Mass | 356.11946368 g/mol |
| Topological Polar Surface Area | 82.7 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 517 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Apricoxib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Apricoxib, including repackagers and relabelers. The FDA regulates Apricoxib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Apricoxib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Apricoxib supplier is an individual or a company that provides Apricoxib active pharmaceutical ingredient (API) or Apricoxib finished formulations upon request. The Apricoxib suppliers may include Apricoxib API manufacturers, exporters, distributors and traders.
click here to find a list of Apricoxib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Apricoxib DMF (Drug Master File) is a document detailing the whole manufacturing process of Apricoxib active pharmaceutical ingredient (API) in detail. Different forms of Apricoxib DMFs exist exist since differing nations have different regulations, such as Apricoxib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Apricoxib DMF submitted to regulatory agencies in the US is known as a USDMF. Apricoxib USDMF includes data on Apricoxib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Apricoxib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Apricoxib suppliers with USDMF on PharmaCompass.
Apricoxib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Apricoxib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Apricoxib GMP manufacturer or Apricoxib GMP API supplier for your needs.
A Apricoxib CoA (Certificate of Analysis) is a formal document that attests to Apricoxib's compliance with Apricoxib specifications and serves as a tool for batch-level quality control.
Apricoxib CoA mostly includes findings from lab analyses of a specific batch. For each Apricoxib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Apricoxib may be tested according to a variety of international standards, such as European Pharmacopoeia (Apricoxib EP), Apricoxib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Apricoxib USP).
LOOKING FOR A SUPPLIER?
